Characterization of uptake of the new PET imaging compound 18F-fluorobenzyl triphenyl phosphonium in dog myocardium

Journal of Nuclear Medicine

Volumn 47, Issue 8, 2006, Pages 1359-1366

  Madar, Igal ^a,b   Ravert, Hayden T ^a   Du, Yong ^a   Hilton, John ^a   Volokh, Lana ^a   Dannals, Robert F ^a   Frost, James J ^a   Hare, Joshua M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JHOC 4230 ^*  (United States)

Author keywords

18F FBnTP; Heart; Imaging; PET

Indexed keywords

FLUOROBENZYL TRIPHENYL PHOSPHONIUM F 18; RADIOISOTOPE; UNCLASSIFIED DRUG; 18F FLUOROBENZYL TRIPHENYL PHOSPHONIUM; 18F-FLUOROBENZYL TRIPHENYL PHOSPHONIUM; FLUORODEOXYGLUCOSE F 18; ORGANOPHOSPHORUS COMPOUND;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERIAL BLOOD; ARTICLE; CONTROLLED STUDY; DEFLUORINATION; DOG; DRUG ACCUMULATION; DRUG RETENTION; DRUG UPTAKE; HEART; HEART MUSCLE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; KIDNEY CORTEX; LIVER; LUNG; MOUSE; NONHUMAN; PLASMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; ANIMAL; CYTOLOGY; FEMALE; HEART MUSCLE CELL; IMAGE PROCESSING; KINETICS; MALE; METHODOLOGY; PATHOLOGY; SCINTISCANNING; WHOLE BODY IMAGING;

ANIMALS; DOGS; FEMALE; FLUORODEOXYGLUCOSE F18; IMAGE PROCESSING, COMPUTER-ASSISTED; KINETICS; LIVER; LUNG; MALE; MYOCARDIUM; MYOCYTES, CARDIAC; ORGANOPHOSPHORUS COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; WHOLE BODY IMAGING;

EID: 33749060656     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Beller GA, Bergmann SR. Myocardial perfusion imaging agents: SPECT and PET. J Nucl Cardiol. 2004;11:71-86.
2. Dondi M, Fagioli G, Salgarello M, et al. Myocardial SPECT: what do we gain from attenuation correction (and when)? Q J Nucl Med Mol Imaging. 2004;48:181-187.
3. Dayanikli F, Grambow D, Muzik O, et al. Early detection of abnormal coronary flow reserve in asymptomatic men at high risk for coronary artery disease using positron emission tomography. Circulation. 1994;90:808-817.
4. Di Carli MF, Janisse J, Grunberger G, Ager J. Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes. J Am Coll Cardiol. 2003;41:1387-1393.
5. Machac J. Cardiac positron emission tomography imaging. Semin Nucl Med. 2005;35:17-36.
6. Krivokapich J, Smith GT, Huang SC, et al. N-13 ammonia myocardial imaging at rest and with exercise in normal volunteers: quantification of absolute myocardial perfusion with dynamic positron emission tomography. Circulation. 1989;80:1328-1337.
7. Schelbert HR, Phelps ME, Huang SC, et al. N-13 ammonia as an indicator of myocardial blood flow. Circulation. 1981;63:1259-1272.
8. 11C]methyl triphenyl phosphonium: measurements of the extraction fraction and myocardial uptake. J Nucl Biol Med. 1994;38:521-526.
9. 18F]-fluorobenzyl triarylphosphonium ions. J Labelled Compds Radiopharm. 2004;47:469-475.
10. O'Rourke B, Kass DA, Tomaselli GF, et al. Mechanisms of altered excitation-contraction coupling in canine tachycardia-induced heart failure. I. experimental studies. Circ Res. 1999;84:562-570.
11. Grinius LL, Jasaitis AA, Kadziauskas YP, et al. Conversion of biomembraneproduced energy into electric form. I. submitochondrial particles. Biochim Biophys Acta. 1970;216:1-12.
12. Murphy MP. Selective targeting of bioactive compounds to mitochondria. Trends Biotechnol. 1997;15:326-330.
13. Madar I, Ravert HT, Nelkin B, et al. Physiochemical characteristics and uptake kinetics of the voltage indicator [F-18]phosphonium cations [abstract]. J Nucl Med. 2003;44(suppl):14P.
14. Kong BA, Shaw L, Miller DD, Chaitman BR. Comparison of accuracy for detecting coronary artery disease and side-effect profile of dipyridamole thallium-201 myocardial perfusion imaging in women versus men. Am J Cardiol. 1992;70:168-173.
15. Nishimura S, Mahmarian JJ, Boyce TM, Verani MS. Quantitative thallium-201 single-photon emission computed tomography during maximal pharmacologic coronary vasodilation with adenosine for assessing coronary artery disease. J Am Coll Cardiol. 1991;18:736-745.
16. Nakajima K, Taki J, Shuke N, Bunko H, Takata S, Hisada K. Myocardial perfusion imaging and dynamic analysis with technetium-99m tetrofosmin. J Nucl Med. 1993;34:1478-1484.
17. Okada RD, Glover D, Gaffney T, Williams S. Myocardial kinetics of technetium-99m-hexakis-2-methoxy-2-methylpropyl-isonitrile. Circulation. 1988;77:491-498.
18. Sinusas AJ, Shi Q, Saltzberg MT, et al. Technetium-99m-tetrofosmin to assess myocardial blood flow: experimental validation in an intact canine model of ischemia. J Nucl Med. 1994;35:664-671.
19. Higley B, Smith FW, Smith T, et al. Technetium-99m-1,2-bis[bis(2- ethoxyethyl) phosphino]ethane: human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent. J Nucl Med. 1993;34:30-38.
20. Nuyts J, Dupont P, Van den Maegdenbergh V, Vleugels S, Suetens P, Mortelmans L. A study of the liver-heart artifact in emission tomography. J Nucl Med. 1995;36:133-139.
21. Kailasnath P, Sinusas AJ. Comparison of Tl-201 with Tc-99m-labeled myocardial perfusion agents: technical, physiologic, and clinical issues. J Nucl Cardiol. 2001;8:482-498.
22. Matsunari I, Fujino S, Taki J, et al. Impaired fatty acid uptake in ischemic but viable myocardium identified by thallium-201 reinjection. Am Heart J. 1996;131:458-465.
23. Boz A, Gungor F, Karayalcin B, Yildiz A. The effects of solid food in prevention of intestinal activity in Tc-99m tetrofosmin myocardial perfusion scintigraphy. J Nucl Cardiol. 2003;10:161-167.
24. Hurwitz GA, Clark EM, Slomka PJ, Siddiq SK. Investigation of measures to reduce interfering abdominal activity on rest myocardial images with Tc-99m sestamibi. Clin Nucl Med. 1993;18:735-741.
25. 99mTc- Tetrofosmin International Trial Study Group. Circulation. 1995;91:313-319.